On April 6, the New York Times reports that the FDA will allow 23andMe to sell genetic tests for disease risk to consumers.  According to the article, customers have to specifically ask to be tested for Alzheimer’s and Parkinson’s risk.

New York Times: F.D.A. Will Allow 23andMe to Sell Genetic Tests for Disease Risk to Consumers